SCHEMBL6538786

SCHEMBL6538786

O=C(OCc1ccccc1)c1ccc(OCC2CC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.59
SLC6A2 P23975 1/20 0.59
SLC6A3 Q01959 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
LMNA P02545 1/20 0.59
PARP10 Q53GL7 5/20 0.56
PARP15 Q460N3 4/20 0.56
PARP2 Q9UGN5 2/20 0.56
CHRNB2 P17787 1/20 0.56
CHRNA5 P30532 1/20 0.56
CHRNA7 P36544 1/20 0.56
CHRNA4 P43681 1/20 0.56
ALDH1A1 P00352 1/20 0.52
MAPT P10636 1/20 0.52
HPGD P15428 1/20 0.52
NR4A1 P22736 1/20 0.51
NR4A2 P43354 1/20 0.51
NR4A3 Q92570 1/20 0.51
DRD2 P14416 1/20 0.49
DRD4 P21917 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9211026 0.89 CHRNB2 (0.65) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL29051137 0.84 KMT2A (0.54) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL22988884 0.84 TDP1 (0.56) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL2525947 0.84 TDP1 (0.56) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL8119333 0.84 TDP1 (0.56) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL50807 0.84 KMT2A (0.73) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL9574756 0.82 KMT2A (0.71) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL51012 0.82 KMT2A (0.71) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL20830742 0.82 CHRNB2 (0.59) KMT2ASLC6A2SLC6A3TDP1LMNA
SCHEMBL29051134 0.81 MEN1 (0.58) KMT2ALMNACHRNB2CHRNA5CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3456713-A1 PROCESS FOR THE PREPARATION OF TRIAZINE DERIVATIVES Japan Tobacco Inc. (JP) 2019-03-20 EP disclosed
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB KMT2A 2770/4885SLC6A2 125/4885SLC6A3 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.